In vitro toxicity assessment of oral nanocarriers

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 381-401

  Ciappellano, Silvia Gabriella ^a   Tedesco, Erik ^a   Venturini, Marco ^a   Benetti, Federico ^a  

^a ECSIN European Center for the Sustainable Impact of Nanotechnology   (Italy)

Author keywords

Drug delivery systems; In vitro assay interferences; In vitro models; In vitro testing; Nanomedicine; Nanotoxicology; Safe by Design; Standard operating procedures

Indexed keywords

ASSAYS; CELL CULTURE; ENZYME INHIBITION; MEDICAL NANOTECHNOLOGY; NANOSTRUCTURED MATERIALS; TARGETED DRUG DELIVERY;

DRUG DELIVERY SYSTEM; IN-VITRO ASSAYS; IN-VITRO MODELS; IN-VITRO TESTING; NANOTOXICOLOGY; STANDARD OPERATING PROCEDURES;

CONTROLLED DRUG DELIVERY;

ATENOLOL; BENZO[A]PYRENE; BLEOMYCIN; CARBON NANOTUBE; CHITOSAN NANOPARTICLE; COLCHICINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXTRAN SULFATE; DOXORUBICIN; ETOPOSIDE; GLUCOSE; GOLD NANOPARTICLE; INSULIN; LEUCINE; LEVODOPA; METOPROLOL; MITOMYCIN; NANOCARRIER; NANOMATERIAL; NAPROXEN; PACLITAXEL; PHENAZONE; SILICA NANOPARTICLE; SILVER NANOPARTICLE; TERBUTALINE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNINDEXED DRUG; VINBLASTINE; ZINC OXIDE NANOPARTICLE; DRUG CARRIER;

APOPTOSIS; AUTOPHAGY; CELL CULTURE; CELL DEATH; CELL VIABILITY ASSAY; CYTOTOXICITY ASSAY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; GENOMICS; GENOTOXICITY; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOTOXICITY; IN VITRO STUDY; INTESTINE FLORA; LIPIDOMICS; METABOLOMICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; TOXICITY TESTING; TRANSCRIPTOMICS; ANIMAL; CELL CULTURE TECHNIQUE; NANOMEDICINE; PROCEDURES; STANDARDS;

ANIMALS; CELL CULTURE TECHNIQUES; DRUG CARRIERS; HUMANS; IN VITRO TECHNIQUES; NANOMEDICINE; NANOSTRUCTURES;

EID: 84995511740     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.08.007     Document Type: Review

References (358)

1. [1] Keiper, A., The nanotechnology revolution. The New Atlantis 2 (2003), 17–34.
2. [2] Linkov, I., Satterstrom, F.K., Corey, L.M., Nanotoxicology and nanomedicine: making hard decisions. Nanomed. Nanotechnol. Biol. Med. 4 (2008), 167–171.
3. [3] Oberdörster, G., Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med. 267 (2010), 89–105.
4. [4] Torchilin, V.P., Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005), 145–160.
5. [5] Jin, S.-E., Jin, H.-E., Hong, S.-S., Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. BioMed Res. Int. 2014 (2014), 1–23.
6. [6] Etheridge, M.L., Campbell, S.A., Erdman, A.G., Haynes, C.L., Wolf, S.M., McCullough, J., The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed. Nanotechnol. Biol. Med. 9 (2013), 1–14.
7. [7] Wang, Y.-X.J., Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant. Imaging Med. Surg., 1, 2011, 35.
8. [8] Somwanshi, S., Dolas, R., Siddheshwar, S., Merekar, A., Godge, R., Pattan, S., Nanomedicine drug delivery system. Asian J. Biomed. Pharm. Sci. 3 (2013), 9–15 (Review).
9. [9] Kagan, V.E., Bayir, H., Shvedova, A.A., Nanomedicine and nanotoxicology: two sides of the same coin. Nanomed. Nanotechnol. Biol. Med. 1 (2005), 313–316.
10. [10] Goldberg, M., Gomez-Orellana, I., Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2 (2003), 289–295.
11. [11] Hirsjarvi, S., Passirani, C., Benoit, J.-P., Passive and active tumour targeting with nanocarriers. Curr. Drug Discov. Technol. 8 (2011), 188–196.
12. [12] Bamrungsap, S., Zhao, Z., Chen, T., Wang, L., Li, C., Fu, T., Tan, W., Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine 7 (2012), 1253–1271.
13. [13] Torchilin, V., Smart pharmaceutical nanocarriers. World Scientific, 2016.
14. [14] Gradishar, W.J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., O'Shaughnessy, J., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. J. Clin. Oncol. 23 (2005), 7794–7803.
15. [15] O'brien, M., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D., Tomczak, P., Ackland, S., Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15 (2004), 440–449.
16. [16] EFSA, Scientific committee, existing approaches incorporating replacement, reduction and refinement of animal testing: applicability in food and feed risk assessment. The EFSA Journal, 1052, 2009.
17. [17] Seo, P.R., Teksin, Z.S., Kao, J.P., Polli, J.E., Lipid composition effect on permeability across PAMPA. Eur. J. Pharm. Sci. 29 (2006), 259–268.
18. [18] Balimane, P.V., Chong, S., Cell culture-based models for intestinal permeability: a critique. Drug Discov. Today 10 (2005), 335–343.
19. [19] Sambuy, Y., De Angelis, I., Ranaldi, G., Scarino, M., Stammati, A., Zucco, F., The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 21 (2005), 1–26.
20. [20] Shahbazi, M.-A., Santos, H.A., Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr. Drug Metab. 14 (2013), 28–56.
21. [21] Hilgendorf, C., Spahn-Langguth, H., Regårdh, C.G., Lipka, E., Amidon, G.L., Langguth, P., Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside-and outside-directed carrier-mediated transport. J. Pharm. Sci. 89 (2000), 63–75.
22. [22] Lennernäs, H., Palm, K., Fagerholm, U., Artursson, P., Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo. Int. J. Pharm. 127 (1996), 103–107.
23. [23] Artursson, P., Palm, K., Luthman, K., Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 64 (2012), 280–289.
24. [24] Chen, X.-M., Elisia, I., Kitts, D.D., Defining conditions for the co-culture of Caco-2 and HT29-MTX cells using Taguchi design. J. Pharmacol. Toxicol. Methods 61 (2010), 334–342.
25. [25] Rocha, R., Vélez, D., Devesa, V., In vitro evaluation of intestinal fluoride absorption using different cell models. Toxicol. Lett. 210 (2012), 311–317.
26. [26] Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
27. [27] Antunes, F., Andrade, F., Araújo, F., Ferreira, D., Sarmento, B., Establishment of a triple co-culture in vitro cell models to study intestinal absorption of peptide drugs. Eur. J. Pharm. Biopharm. 83 (2013), 427–435.
28. [28] Kucharzik, T., Lügering, N., Rautenberg, K., Lügering, A., Schmidt, M., Stoll, R., Domschke, W., Role of M cells in intestinal barrier function. Ann. N. Y. Acad. Sci. 915 (2000), 171–183.
29. [29] Rieux, A.d., Fievez, V., Garinot, M., Schneider, Y.-J., Préat, V., Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006), 1–27.
30. [30] Florence, A.T., Issues in oral nanoparticle drug carrier uptake and targeting. J. Drug Target. 12 (2004), 65–70.
31. [31] Meunier, V., Bourrie, M., Berger, Y., Fabre, G., The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol. Toxicol. 11 (1995), 187–194.
32. [32] Gerloff, K., Pereira, D.I., Faria, N., Boots, A.W., Kolling, J., Förster, I., Albrecht, C., Powell, J.J., Schins, R.P., Influence of simulated gastrointestinal conditions on particle-induced cytotoxicity and interleukin-8 regulation in differentiated and undifferentiated Caco-2 cells. Nanotoxicology 7 (2013), 353–366.
33. [33] Shappell, N.W., Ergovaline toxicity on Caco-2 cells as assessed by MTT, alamarBlue, and DNA assays. In Vitro Cell. Dev. Biol. Anim. 39 (2003), 329–335.
34. [34] Böhmert, L., Girod, M., Hansen, U., Maul, R., Knappe, P., Niemann, B., Weidner, S.M., Thünemann, A.F., Lampen, A., Analytically monitored digestion of silver nanoparticles and their toxicity on human intestinal cells. Nanotoxicology 8 (2014), 631–642.
35. [35] Walczak, A.P., Fokkink, R., Peters, R., Tromp, P., Herrera Rivera, Z.E., Rietjens, I.M., Hendriksen, P.J., Bouwmeester, H., Behaviour of silver nanoparticles and silver ions in an in vitro human gastrointestinal digestion model. Nanotoxicology 7 (2012), 1198–1210.
36. [36] Jos, A., Pichardo, S., Puerto, M., Sánchez, E., Grilo, A., Cameán, A.M., Cytotoxicity of carboxylic acid functionalized single wall carbon nanotubes on the human intestinal cell line Caco-2. Toxicol. in Vitro 23 (2009), 1491–1496.
37. [37] Speckmann, B., Pinto, A., Winter, M., Förster, I., Sies, H., Steinbrenner, H., Proinflammatory cytokines down-regulate intestinal selenoprotein P biosynthesis via NOS2 induction. Free Radic. Biol. Med. 49 (2010), 777–785.
38. [38] Nel, A., Xia, T., Mädler, L., Li, N., Toxic potential of materials at the nanolevel. Science 311 (2006), 622–627.
39. [39] Quan, Y.-s., Hattori, K., Lundborg, E., Fujita, T., Murakami, M., Muranishi, S., Yamamoto, A., Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers. Biol. Pharm. Bull. 21 (1998), 615–620.
40. [40] Konsoula, R., Barile, F.A., Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol. in Vitro 19 (2005), 675–684.
41. [41] Coyuco, J.C., Liu, Y., Tan, B.-J., Chiu, G.N., Functionalized carbon nanomaterials: exploring the interactions with Caco-2 cells for potential oral drug delivery. Int. J. Nanomedicine, 6, 2011, 2253.
42. [42] Hughes, P., Marshall, D., Reid, Y., Parkes, H., Gelber, C., The costs of using unauthenticated, over-passaged cell lines: how much more data do we need?. Biotechniques, 43, 2007, 575.
43. [43] Bergin, I.L., Witzmann, F.A., Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps. Int. J. Biomed. Nanosci. Nanotechnol. 3 (2013), 163–210.
44. [44] Bu, Q., Yan, G., Deng, P., Peng, F., Lin, H., Xu, Y., Cao, Z., Zhou, T., Xue, A., Wang, Y., NMR-based metabonomic study of the sub-acute toxicity of titanium dioxide nanoparticles in rats after oral administration. Nanotechnology, 21, 2010, 125105.
45. [45] Cattani, V.B., Fiel, L.A., Jäger, A., Jäger, E., Colomé, L.M., Uchoa, F., Stefani, V., Dalla Costa, T., Guterres, S.S., Pohlmann, A.R., Lipid-core nanocapsules restrained the indomethacin ethyl ester hydrolysis in the gastrointestinal lumen and wall acting as mucoadhesive reservoirs. Eur. J. Pharm. Sci. 39 (2010), 116–124.
46. [46] Shanahan, F., The colonic microbiota and colonic disease. Curr. Gastroenterol. Rep. 14 (2012), 446–452.
47. [47] Sekirov, I., Russell, S.L., Antunes, L.C.M., Finlay, B.B., Gut microbiota in health and disease. Physiol. Rev. 90 (2010), 859–904.
48. [48] Roeselers, G., Bouwman, J., Venema, K., Montijn, R., The human gastrointestinal microbiota—an unexplored frontier for pharmaceutical discovery. Pharmacol. Res. 66 (2012), 443–447.
49. [49] Venema, K., Role of gut microbiota in the control of energy and carbohydrate metabolism. Curr. Opin. Clin. Nutr. Metab. Care 13 (2010), 432–438.
50. [50] Clemente, J.C., Ursell, L.K., Parfrey, L.W., Knight, R., The impact of the gut microbiota on human health: an integrative view. Cell 148 (2012), 1258–1270.
51. [51] Flint, H.J., Scott, K.P., Louis, P., Duncan, S.H., The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 9 (2012), 577–589.
52. [52] Cryan, J.F., Dinan, T.G., Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13 (2012), 701–712.
53. [53] Sommer, F., Bäckhed, F., The gut microbiota—masters of host development and physiology. Nat. Rev. Microbiol. 11 (2013), 227–238.
54. [54] Macfarlane, G., Blackett, K., Nakayama, T., Steed, H., Macfarlane, S., The gut microbiota in inflammatory bowel disease. Curr. Pharm. Des. 15 (2009), 1528–1536.
55. [55] Ley, R.E., Peterson, D.A., Gordon, J.I., Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124 (2006), 837–848.
56. [56] Young, V.B., The intestinal microbiota in health and disease. Curr. Opin. Gastroenterol., 28, 2012, 63.
57. [57] Huffnagle, G.B., Noverr, M., GI Microbiota and Regulation of the Immune System. 2009, Springer Science & Business Media.
58. [58] Atarashi, K., Honda, K., Microbiota in autoimmunity and tolerance. Curr. Opin. Immunol. 23 (2011), 761–768.
59. [59] Hadrup, N., Loeschner, K., Bergström, A., Wilcks, A., Gao, X., Vogel, U., Frandsen, H.L., Larsen, E.H., Lam, H.R., Mortensen, A., Subacute oral toxicity investigation of nanoparticulate and ionic silver in rats. Arch. Toxicol. 86 (2012), 543–551.
60. [60] Williams, K., Milner, J., Boudreau, M.D., Gokulan, K., Cerniglia, C.E., Khare, S., Effects of subchronic exposure of silver nanoparticles on intestinal microbiota and gut-associated immune responses in the ileum of Sprague-Dawley rats. Nanotoxicology 9 (2015), 279–289.
61. [61] Rehman, A., Heinsen, F.-A., Koenen, M.E., Venema, K., Knecht, H., Hellmig, S., Schreiber, S., Ott, S.J., Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine. BMC Microbiol., 12, 2012, 47.
62. [62] Maathuis, A.J., van den Heuvel, E.G., Schoterman, M.H., Venema, K., Galacto-oligosaccharides have prebiotic activity in a dynamic in vitro colon model using a 13C-labeling technique. J. Nutr. 142 (2012), 1205–1212.
63. [63] Van Nuenen, M.H., Venema, K., Van Der Woude, J.C., Kuipers, E.J., The metabolic activity of fecal microbiota from healthy individuals and patients with inflammatory bowel disease. Dig. Dis. Sci. 49 (2004), 485–491.
64. [64] Daguet, D., Pinheiro, I., Verhelst, A., Possemiers, S., Marzorati, M., Arabinogalactan and fructooligosaccharides improve the gut barrier function in distinct areas of the colon in the simulator of the human intestinal microbial ecosystem. J. Funct. Foods 20 (2016), 369–379.
65. [65] Veiga, P., Pons, N., Agrawal, A., Oozeer, R., Guyonnet, D., Brazeilles, R., Faurie, J.-M., van Hylckama Vlieg, J.E., Houghton, L.A., Whorwell, P.J., Changes of the human gut microbiome induced by a fermented milk product. Sci. Report., 4, 2014.
66. [66] Van de Wiele, T., Van den Abbeele, P., Ossieur, W., Possemiers, S., Marzorati, M., The Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), the Impact of Food Bioactives on Health. 2015, Springer, 305–317.
67. [67] Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., Yamada, T., A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464 (2010), 59–65.
68. [68] Walczak, A.P., Kramer, E., Hendriksen, P.J., Tromp, P., Helsper, J.P., van der Zande, M., Rietjens, I.M., Bouwmeester, H., Translocation of differently sized and charged polystyrene nanoparticles in in vitro intestinal cell models of increasing complexity. Nanotoxicology 9 (2015), 453–461.
69. [69] Gamboa, J.M., Leong, K.W., In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv. Drug Deliv. Rev. 65 (2013), 800–810.
70. [70] EFSA, Scientific committee, guidance on the risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain. EFSA J., 9, 2011, 2140.
71. [71] B.P. Commission, Artificial Gastric Juice. 2014, The British Pharmacopoeia, TSO, London, 1727.
72. [72] Ren, J., Williams, P.N., Luo, J., Ma, H., Wang, X., Sediment metal bioavailability in Lake Taihu, China: evaluation of sequential extraction, DGT, and PBET techniques. Environ. Sci. Pollut. Res., 2015, 1–10.
73. [73] Li, Y., Zhang, M.-k., A comparison of physiologically based extraction test (PBET) and single-extraction methods for release of Cu, Zn, and Pb from mildly acidic and alkali soils. Environ. Sci. Pollut. Res. 20 (2013), 3140–3148.
74. [74] Tilston, E.L., Gibson, G.R., Collins, C.D., Colon extended physiologically based extraction test (CE-PBET) increases bioaccessibility of soil-bound PAH. Environ. Sci. Technol. 45 (2011), 5301–5308.
75. [75] Frank, K., Walz, E., Gräf, V., Greiner, R., Köhler, K., Schuchmann, H.P., Stability of anthocyanin-rich W/O/W-emulsions designed for intestinal release in gastrointestinal environment. J. Food Sci. 77 (2012), N50–N57.
76. [76] Merkel, S., Dib, B., Maul, R., Köppen, R., Koch, M., Nehls, I., Degradation and epimerization of ergot alkaloids after baking and in vitro digestion. Anal. Bioanal. Chem. 404 (2012), 2489–2497.
77. [77] Guney, M., Nguyen, A., Zagury, G.J., Estimating children's exposure to toxic elements in contaminated toys and children's jewelry via saliva mobilization. J. Environ. Sci. Health A 49 (2014), 1218–1227.
78. [78] Omar, N., Praveena, S., Aris, A., Hashim, Z., Health risk assessment using in vitro digestion model in assessing bioavailability of heavy metal in rice: a preliminary study. Food Chem. 188 (2015), 46–50.
79. [79] Ozbey, F., Kabak, B., Natural co-occurrence of aflatoxins and ochratoxin A in spices. Food Control 28 (2012), 354–361.
80. [80] Altundag, H., Albayrak, S., Dundar, M.S., Tuzen, M., Soylak, M., Investigation of the influence of selected soil and plant properties from Sakarya, Turkey, on the bioavailability of trace elements by applying an in vitro digestion model. Biol. Trace Elem. Res., 2015, 1–10.
81. [81] Van Hecke, T., Vanden Bussche, J., Vanhaecke, L., Vossen, E., Van Camp, J., De Smet, S., Nitrite curing of chicken, pork, and beef inhibits oxidation but does not affect N-nitroso compound (NOC)-specific DNA adduct formation during in vitro digestion. J. Agric. Food Chem. 62 (2014), 1980–1988.
82. [82] Sun, G.-X., Van de Wiele, T., Alava, P., Tack, F., Laing, G.D., Arsenic in cooked rice: effect of chemical, enzymatic and microbial processes on bioaccessibility and speciation in the human gastrointestinal tract. Environ. Pollut. 162 (2012), 241–246.
83. [83] Verwei, M., Minekus, M., Zeijdner, E., Schilderink, R., Havenaar, R., Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms. Int. J. Pharm. 498 (2016), 178–186.
84. [84] Ribnicky, D.M., Roopchand, D.E., Oren, A., Grace, M., Poulev, A., Lila, M.A., Havenaar, R., Raskin, I., Effects of a high fat meal matrix and protein complexation on the bioaccessibility of blueberry anthocyanins using the TNO gastrointestinal model (TIM-1). Food Chem. 142 (2014), 349–357.
85. [85] Uriot, O., Galia, W., Awussi, A.A., Perrin, C., Denis, S., Chalancon, S., Lorson, E., Poirson, C., Junjua, M., Le Roux, Y., Use of the dynamic gastro-intestinal model TIM to explore the survival of the yogurt bacterium Streptococcus thermophilus and the metabolic activities induced in the simulated human gut. Food Microbiol., 2015.
86. [86] Van de Wiele, T.R., Oomen, A.G., Wragg, J., Cave, M., Minekus, M., Hack, A., Cornelis, C., Rompelberg, C.J., De Zwart, L.L., Klinck, B., Comparison of five in vitro digestion models to in vivo experimental results: lead bioaccessibility in the human gastrointestinal tract. J. Environ. Sci. Health A 42 (2007), 1203–1211.
87. [87] Versantvoort, C.H., Oomen, A.G., Van de Kamp, E., Rompelberg, C.J., Sips, A.J., Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins from food. Food Chem. Toxicol. 43 (2005), 31–40.
88. [88] van Duinen, V., Trietsch, S.J., Joore, J., Vulto, P., Hankemeier, T., Microfluidic 3D cell culture: from tools to tissue models. Curr. Opin. Biotechnol. 35 (2015), 118–126.
89. [89] Valencia, P.M., Farokhzad, O.C., Karnik, R., Langer, R., Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat. Nanotechnol. 7 (2012), 623–629.
90. [90] Ghaemmaghami, A.M., Hancock, M.J., Harrington, H., Kaji, H., Khademhosseini, A., Biomimetic tissues on a chip for drug discovery. Drug Discov. Today 17 (2012), 173–181.
91. [91] Kim, H.J., Huh, D., Hamilton, G., Ingber, D.E., Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12 (2012), 2165–2174.
92. [92] Tsui, J.H., Lee, W., Pun, S.H., Kim, J., Kim, D.-H., Microfluidics-assisted in vitro drug screening and carrier production. Adv. Drug Deliv. Rev. 65 (2013), 1575–1588.
93. [93] Imura, Y., Asano, Y., Sato, K., Yoshimura, E., A microfluidic system to evaluate intestinal absorption. Anal. Sci. 25 (2009), 1403–1407.
94. [94] Kimura, H., Ikeda, T., Nakayama, H., Sakai, Y., Fujii, T., An on-chip small intestine–liver model for pharmacokinetic studies. J. Lab. Autom. 20 (2015), 265–273.
95. [95] Shuler, M.L., Esch, M.B., Body-on-a chip: using microfluidic systems to predict human responses to drugs. Pure Appl. Chem. 82 (2010), 1635–1645.
96. [96] Huh, D., Torisawa, Y.-s., Hamilton, G.A., Kim, H.J., Ingber, D.E., Microengineered physiological biomimicry: organs-on-chips. Lab Chip 12 (2012), 2156–2164.
97. [97] Benetti, F., Bregoli, L., Olivato, I., Sabbioni, E., Effects of metal (loid)-based nanomaterials on essential element homeostasis: the central role of nanometallomics for nanotoxicology. Metallomics 6 (2014), 729–747.
98. [98] Ong, K.J., MacCormack, T.J., Clark, R.J., Ede, J.D., Ortega, V.A., Felix, L.C., Dang, M.K., Ma, G., Fenniri, H., Veinot, J.G., Widespread nanoparticle-assay interference: implications for nanotoxicity testing. PLoS One, 9, 2014, e90650.
99. [99] Gonzalez-Moragas, L., Roig, A., Laromaine, A., C. elegans as a tool for in vivo nanoparticle assessment. Adv. Colloid Interf. Sci. 219 (2015), 10–26.
100. [100] Charao, M.F., Souto, C., Brucker, N., Barth, A., Jornada, D.S., Fagundez, D., Ávila, D.S., Eifler-Lima, V.L., Guterres, S.S., Pohlmann, A.R., Caenorhabditis elegans as an alternative in vivo model to determine oral uptake, nanotoxicity, and efficacy of melatonin-loaded lipid-core nanocapsules on paraquat damage. Int. J. Nanomedicine, 10, 2015, 5093.
101. [101] Qu, Y., Li, W., Zhou, Y., Liu, X., Zhang, L., Wang, L., Li, Y.-f., Iida, A., Tang, Z., Zhao, Y., Full assessment of fate and physiological behavior of quantum dots utilizing Caenorhabditis elegans as a model organism. Nano Lett. 11 (2011), 3174–3183.
102. [102] Fangueiro, J., Gonzalez-Mira, E., Martins-Lopes, P., Egea, M., Garcia, M., Souto, S., Souto, E.B., A novel lipid nanocarrier for insulin delivery: production, characterization and toxicity testing. Pharm. Dev. Technol. 18 (2013), 545–549.
103. [103] Buzea, C., Pacheco, I.I., Robbie, K., Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2 (2007), MR17–MR71.
104. [104] Dhawan, A., Sharma, V., Toxicity assessment of nanomaterials: methods and challenges. Anal. Bioanal. Chem. 398 (2010), 589–605.
105. [105] Love, S.A., Maurer-Jones, M.A., Thompson, J.W., Lin, Y.-S., Haynes, C.L., Assessing nanoparticle toxicity. Annu. Rev. Anal. Chem. 5 (2012), 181–205.
106. [106] Meng, H., Xia, T., George, S., Nel, A.E., A predictive toxicological paradigm for the safety assessment of nanomaterials. ACS Nano 3 (2009), 1620–1627.
107. [107] Stone, V., Nowack, B., Baun, A., van den Brink, N., von der Kammer, F., Dusinska, M., Handy, R., Hankin, S., Hassellöv, M., Joner, E., Nanomaterials for environmental studies: classification, reference material issues, and strategies for physico-chemical characterisation. Sci. Total Environ. 408 (2010), 1745–1754.
108. [108] Wolfram, J., Zhu, M., Yang, Y., Shen, J., Gentile, E., Paolino, D., Fresta, M., Nie, G., Chen, C., Shen, H., Safety of nanoparticles in medicine. Curr. Drug Targets, 2014.
109. [109] Locascio, L.E., Reipa, V., Zook, J.M., Pleus, R.C., Nanomaterial Toxicity: Emerging Standards and Efforts to Support Standards Development, Nanotechnology Standards. 2011, Springer, 179–208.
110. [110] Yang, H., Liu, C., Yang, D., Zhang, H., Xi, Z., Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. J. Appl. Toxicol. 29 (2009), 69–78.
111. [111] Liu, W., Wu, Y., Wang, C., Li, H.C., Wang, T., Liao, C.Y., Cui, L., Zhou, Q.F., Yan, B., Jiang, G.B., Impact of silver nanoparticles on human cells: effect of particle size. Nanotoxicology 4 (2010), 319–330.
112. [112] Ivask, A., Kurvet, I., Kasemets, K., Blinova, I., Aruoja, V., Suppi, S., Vija, H., Käkinen, A., Titma, T., Heinlaan, M., Size-dependent toxicity of silver nanoparticles to bacteria, yeast, algae. Crustac. Mamm. Cells In Vitro 9 (2014), 1–14.
113. [113] Nel, A.E., Mädler, L., Velegol, D., Xia, T., Hoek, E.M., Somasundaran, P., Klaessig, F., Castranova, V., Thompson, M., Understanding biophysicochemical interactions at the nano–bio interface. Nat. Mater. 8 (2009), 543–557.
114. [114] Gliga, A.R., Skoglund, S., Wallinder, I.O., Fadeel, B., Karlsson, H.L., Size-dependent cytotoxicity of silver nanoparticles in human lung cells: the role of cellular uptake, agglomeration and Ag release. Part. Fibre Toxicol. 11 (2014), 1–17.
115. [115] Misra, S.K., Dybowska, A., Berhanu, D., Luoma, S.N., Valsami-Jones, E., The complexity of nanoparticle dissolution and its importance in nanotoxicological studies. Sci. Total Environ. 438 (2012), 225–232.
116. [116] Kittler, S., Greulich, C., Diendorf, J., Koller, M., Epple, M., Toxicity of silver nanoparticles increases during storage because of slow dissolution under release of silver ions. Chem. Mater. 22 (2010), 4548–4554.
117. [117] Cho, W.-S., Duffin, R., Thielbeer, F., Bradley, M., Megson, I.L., MacNee, W., Poland, C.A., Tran, C.L., Donaldson, K., Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal-oxide nanoparticles. Toxicological Sciences, 2012, kfs006.
118. [118] Food Drug Administration, Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Color Additives-Draft Guidance. Book Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Color Additives-Draft Guidance, 2012.
119. [119] OECD, Test No. 471: Bacterial Reverse Mutation Test, OECD Publishing.
120. [120] OECD, Important Issues on Risk Assessment of Manufactured Nanomaterials OECD. Environment, Health and Safety Publications Series on the Safety of Manufactured Nanomaterials ENV/JM/MONO (2012), 8, 2012.
121. [121] OECD, Guidance Manual for the Testing of Manufactured Nanomaterials: OECD's Sponsorship Programme; First Revision OECD. Environment, Health and Safety Publications Series on the Safety of Manufactured Nanomaterials ENV/JM/MONO(2009)20/REV, 2010.
122. [122] Rieux, A.d., Fievez, V., Théate, I., Mast, J., Préat, V., Schneider, Y.-J., An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur. J. Pharm. Sci. 30 (2007), 380–391.
123. [123] Artursson, P., Karlsson, J., Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991), 880–885.
124. [124] Kroll, A., Pillukat, M.H., Hahn, D., Schnekenburger, J., Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur. J. Pharm. Biopharm. 72 (2009), 370–377.
125. [125] Marquis, B.J., Love, S.A., Braun, K.L., Haynes, C.L., Analytical methods to assess nanoparticle toxicity. Analyst 134 (2009), 425–439.
126. [126] Oostingh, G.J., Casals, E., Italiani, P., Colognato, R., Stritzinger, R., Ponti, J., Pfaller, T., Kohl, Y., Ooms, D., Favilli, F., Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part. Fibre Toxicol., 8, 2011, 8.
127. [127] Kroll, A., Pillukat, M.H., Hahn, D., Schnekenburger, J., Interference of engineered nanoparticles with in vitro toxicity assays. Arch. Toxicol. 86 (2012), 1123–1136.
128. [128] Han, X., Gelein, R., Corson, N., Wade-Mercer, P., Jiang, J., Biswas, P., Finkelstein, J.N., Elder, A., Oberdörster, G., Validation of an LDH assay for assessing nanoparticle toxicity. Toxicology 287 (2011), 99–104.
129. [129] Costa, C., Brandão, F., Bessa, M.J., Costa, S., Valdiglesias, V., Kiliç, G., Fernández-Bertólez, N., Quaresma, P., Pereira, E., Pásaro, E., In vitro cytotoxicity of superparamagnetic iron oxide nanoparticles on neuronal and glial cells. Evaluation of nanoparticle interference with viability tests. J. Appl. Toxicol. 36 (2015), 361–372.
130. [130] Si, D.-Y., Sun, Y., Cheng, T., Liu, C., Biomedical evaluation of nanomedicines. Asian J. Pharmacodyn. Pharmacokinet. 7 (2007), 83–97.
131. [131] AshaRani, P., Mun, G.L.K., Hande, M.P., Valiyaveettil, S., Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3 (2008), 279–290.
132. [132] Horev-Azaria, L., Kirkpatrick, C.J., Korenstein, R., Marche, P.N., Maimon, O., Ponti, J., Romano, R., Rossi, F., Golla-Schindler, U., Sommer, D., Predictive toxicology of cobalt nanoparticles and ions: comparative in vitro study of different cellular models using methods of knowledge discovery from data. Toxicol. Sci., 122, 2011.
133. [133] Mukherjee, S.G., O'Claonadh, N., Casey, A., Chambers, G., Comparative in vitro cytotoxicity study of silver nanoparticle on two mammalian cell lines. Toxicol. in Vitro 26 (2012), 238–251.
134. [134] Ahamed, M., Toxic response of nickel nanoparticles in human lung epithelial A549 cells. Toxicol. in Vitro 25 (2011), 930–936.
135. [135] Malvindi, M.A., De Matteis, V., Galeone, A., Brunetti, V., Anyfantis, G.C., Athanassiou, A., Cingolani, R., Pompa, P.P., Toxicity Assessment of Silica Coated Iron Oxide Nanoparticles and Biocompatibility Improvement by Surface Engineering. 2014.
136. [136] Barillet, S., Simon-Deckers, A., Herlin-Boime, N., Mayne-L'Hermite, M., Reynaud, C., Cassio, D., Gouget, B., Carrière, M., Toxicological consequences of TiO2, SiC nanoparticles and multi-walled carbon nanotubes exposure in several mammalian cell types: an in vitro study. J. Nanopart. Res. 12 (2010), 61–73.
137. [137] Fisichella, M., Berenguer, F., Steinmetz, G., Auffan, M., Rose, J., Prat, O., Intestinal toxicity evaluation of TiO2 degraded surface-treated nanoparticles: a combined physico-chemical and toxicogenomics approach in caco-2 cells. Part. Fibre Toxicol., 9, 2012, 18.
138. [138] Lanone, S., Rogerieux, F., Geys, J., Dupont, A., Maillot-Marechal, E., Boczkowski, J., Lacroix, G., Hoet, P., Comparative toxicity of 24 manufactured nanoparticles in human alveolar epithelial and macrophage cell lines. Part. Fibre Toxicol. 6 (2009), 455–460.
139. [139] Singh, R.P., Ramarao, P., Cellular uptake, intracellular trafficking and cytotoxicity of silver nanoparticles. Toxicol. Lett. 213 (2012), 249–259.
140. [140] Zhao, J., Bowman, L., Zhang, X., Shi, X., Jiang, B., Castranova, V., Ding, M., Metallic nickel nano-and fine particles induce JB6 cell apoptosis through a caspase-8/AIF mediated cytochrome c-independent pathway. J. Nanobiotechnol., 7, 2009.
141. [141] Kwon, Y.-M., Xia, Z., Glyn-Jones, S., Beard, D., Gill, H.S., Murray, D.W., Dose-dependent cytotoxicity of clinically relevant cobalt nanoparticles and ions on macrophages in vitro. Biomed. Mater., 4, 2009, 025018.
142. [142] Foldbjerg, R., Olesen, P., Hougaard, M., Dang, D.A., Hoffmann, H.J., Autrup, H., PVP-coated silver nanoparticles and silver ions induce reactive oxygen species, apoptosis and necrosis in THP-1 monocytes. Toxicol. Lett. 190 (2009), 156–162.
143. [143] Zhang, T., Wang, L., Chen, Q., Chen, C., Cytotoxic potential of silver nanoparticles. Yonsei Med. J. 55 (2014), 283–291.
144. [144] Park, E.-J., Yi, J., Kim, Y., Choi, K., Park, K., Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol. in Vitro 24 (2010), 872–878.
145. [145] Jiang, H., Liu, F., Yang, H., Li, Y., Effects of cobalt nanoparticles on human T cells in vitro. Biol. Trace Elem. Res. 146 (2012), 23–29.
146. [146] Worthington, K.L., Adamcakova-Dodd, A., Wongrakpanich, A., Mudunkotuwa, I.A., Mapuskar, K.A., Joshi, V.B., Guymon, C.A., Spitz, D.R., Grassian, V.H., Thorne, P.S., Chitosan coating of copper nanoparticles reduces in vitro toxicity and increases inflammation in the lung. Nanotechnology, 24, 2013, 395101.
147. [147] Smith, W.E., Brownell, J., White, C.C., Afsharinejad, Z., Tsai, J., Hu, X., Polyak, S.J., Gao, X., Kavanagh, T.J., Eaton, D.L., In vitro toxicity assessment of amphiphillic polymer-coated CdSe/ZnS quantum dots in two human liver cell models. ACS Nano 6 (2012), 9475–9484.
148. [148] Wang, X., Ji, Z., Chang, C.H., Zhang, H., Wang, M., Liao, Y.P., Lin, S., Meng, H., Li, R., Sun, B., Use of coated silver nanoparticles to understand the relationship of particle dissolution and bioavailability to cell and lung toxicological potential. Small 10 (2014), 385–398.
149. [149] Lewinski, N., Colvin, V., Drezek, R., Cytotoxicity of nanoparticles. Small 4 (2008), 26–49.
150. [150] Jones, C.F., Grainger, D.W., In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev. 61 (2009), 438–456.
151. [151] Wan, R., Mo, Y., Feng, L., Chien, S., Tollerud, D.J., Zhang, Q., DNA damage caused by metal nanoparticles: involvement of oxidative stress and activation of ATM†. Chem. Res. Toxicol. 25 (2012), 1402–1411.
152. [152] Miura, N., Shinohara, Y., Cytotoxic effect and apoptosis induction by silver nanoparticles in HeLa cells. Biochem. Biophys. Res. Commun. 390 (2009), 733–737.
153. [153] Tedesco, E., Mičetić, I., Ciappellano, S.G., Micheletti, C., Venturini, M., Benetti, F., Cytotoxicity and antibacterial activity of a new generation of nanoparticle-based consolidants for restoration and contribution to the safe-by-design implementation. Toxicol. in Vitro 29 (2015), 1736–1744.
154. [154] Phenrat, T., Long, T.C., Lowry, G.V., Veronesi, B., Partial oxidation (“aging”) and surface modification decrease the toxicity of nanosized zerovalent iron. Environ. Sci. Technol. 43 (2008), 195–200.
155. [155] Zhang, H., Ji, Z., Xia, T., Meng, H., Low-Kam, C., Liu, R., Pokhrel, S., Lin, S., Wang, X., Liao, Y.-P., Use of metal oxide nanoparticle band gap to develop a predictive paradigm for oxidative stress and acute pulmonary inflammation. ACS Nano 6 (2012), 4349–4368.
156. [156] Bimbo, L.M., Mäkilä, E., Laaksonen, T., Lehto, V.-P., Salonen, J., Hirvonen, J., Santos, H.A., Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. Biomaterials 32 (2011), 2625–2633.
157. [157] Papis, E., Gornati, R., Prati, M., Ponti, J., Sabbioni, E., Bernardini, G., Gene expression in nanotoxicology research: analysis by differential display in BALB3T3 fibroblasts exposed to cobalt particles and ions. Toxicol. Lett. 170 (2007), 185–192.
158. [158] DIMITRIJEVIC, D., SHAW, A.J., FLORENCE, A.T., Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells. J. Pharm. Pharmacol. 52 (2000), 157–162.
159. [159] Koeneman, B.A., Zhang, Y., Westerhoff, P., Chen, Y., Crittenden, J.C., Capco, D.G., Toxicity and cellular responses of intestinal cells exposed to titanium dioxide. Cell Biol. Toxicol. 26 (2010), 225–238.
160. [160] Vllasaliu, D., Exposito-Harris, R., Heras, A., Casettari, L., Garnett, M., Illum, L., Stolnik, S., Tight junction modulation by chitosan nanoparticles: comparison with chitosan solution. Int. J. Pharm. 400 (2010), 183–193.
161. [161] Duizer, E., Van Der Wulp, C., Versantvoort, C.H., Groten, J.P., Absorption enhancement, structural changes in tight junctions and cytotoxicity caused by palmitoyl carnitine in Caco-2 and IEC-18 cells. J. Pharmacol. Exp. Ther. 287 (1998), 395–402.
162. [162] El-Sayed, M., Ginski, M., Rhodes, C., Ghandehari, H., Transepithelial transport of poly (amidoamine) dendrimers across Caco-2 cell monolayers. J. Control. Release 81 (2002), 355–365.
163. [163] Elamin, E., Jonkers, D., Juuti-Uusitalo, K., van IJzendoorn, S., Troost, F., Duimel, H., Broers, J., Verheyen, F., Dekker, J., Masclee, A., Effects of ethanol and acetaldehyde on tight junction integrity: in vitro study in a three dimensional intestinal epithelial cell culture model. PLoS One, 7, 2012, e35008.
164. [164] Ferruzza, S., Scarino, M.-L., Rotilio, G., Ciriolo, M.R., Santaroni, P., Muda, A.O., Sambuy, Y., Copper treatment alters the permeability of tight junctions in cultured human intestinal Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 277 (1999), G1138–G1148.
165. [165] Wilhelmi, V., Fischer, U., van Berlo, D., Schulze-Osthoff, K., Schins, R.P., Albrecht, C., Evaluation of apoptosis induced by nanoparticles and fine particles in RAW 264.7 macrophages: facts and artefacts. Toxicol. in Vitro 26 (2012), 323–334.
166. [166] Beer, C., Foldbjerg, R., Hayashi, Y., Sutherland, D.S., Autrup, H., Toxicity of silver nanoparticles—nanoparticle or silver ion?. Toxicol. Lett. 208 (2012), 286–292.
167. [167] Hsin, Y.-H., Chen, C.-F., Huang, S., Shih, T.-S., Lai, P.-S., Chueh, P.J., The apoptotic effect of nanosilver is mediated by a ROS-and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells. Toxicol. Lett. 179 (2008), 130–139.
168. [168] Böhmert, L., Niemann, B., Thünemann, A.F., Lampen, A., Cytotoxicity of peptide-coated silver nanoparticles on the human intestinal cell line Caco-2. Arch. Toxicol. 86 (2012), 1107–1115.
169. [169] Foldbjerg, R., Dang, D.A., Autrup, H., Cytotoxicity and genotoxicity of silver nanoparticles in the human lung cancer cell line, A549. Arch. Toxicol. 85 (2011), 743–750.
170. [170] Girnun, G.D., Naseri, E., Vafai, S.B., Qu, L., Szwaya, J.D., Bronson, R., Alberta, J.A., Spiegelman, B.M., Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell 11 (2007), 395–406.
171. [171] Giovannini, C., Sanchez, M., Straface, E., Scazzocchio, B., Silano, M., De Vincenzi, M., Induction of apoptosis in caco-2 cells by wheat gliadin peptides. Toxicology 145 (2000), 63–71.
172. [172] Suri, S., Mönkkönen, J., Taskinen, M., Pesonen, J., Blank, M., Phipps, R., Rogers, M., Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29 (2001), 336–343.
173. [173] Berghe, T.V., Grootjans, S., Goossens, V., Dondelinger, Y., Krysko, D.V., Takahashi, N., Vandenabeele, P., Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods 61 (2013), 117–129.
174. [174] Krysko, D.V., Vanden Berghe, T., D'Herde, K., Vandenabeele, P., Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 44 (2008), 205–221.
175. [175] George, S., Pokhrel, S., Xia, T., Gilbert, B., Ji, Z., Schowalter, M., Rosenauer, A., Damoiseaux, R., Bradley, K.A., Mädler, L., Use of a rapid cytotoxicity screening approach to engineer a safer zinc oxide nanoparticle through iron doping. ACS Nano 4 (2009), 15–29.
176. [176] Nel, A., Xia, T., Meng, H., Wang, X., Lin, S., Ji, Z., Zhang, H., Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-throughput screening. Acc. Chem. Res. 46 (2012), 607–621.
177. [177] Martinez-Gutierrez, F., Olive, P.L., Banuelos, A., Orrantia, E., Nino, N., Sanchez, E.M., Ruiz, F., Bach, H., Av-Gay, Y., Synthesis, characterization, and evaluation of antimicrobial and cytotoxic effect of silver and titanium nanoparticles. Nanomed. Nanotechnol. Biol. Med. 6 (2010), 681–688.
178. [178] Beloqui, A., Solinís, M.Á., Rieux, A.d., Préat, V., Rodríguez-Gascón, A., Dextran–protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int. J. Pharm. 468 (2014), 105–111.
179. [179] Holder, A.L., Goth-Goldstein, R., Lucas, D., Koshland, C.P., Particle-induced artifacts in the MTT and LDH viability assays. Chem. Res. Toxicol. 25 (2012), 1885–1892.
180. [180] Hussain, S., Hess, K., Gearhart, J., Geiss, K., Schlager, J., In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol. in Vitro 19 (2005), 975–983.
181. [181] Keenan, C.R., Goth-Goldstein, R., Lucas, D., Sedlak, D.L., Oxidative stress induced by zero-valent iron nanoparticles and Fe (II) in human bronchial epithelial cells. Environ. Sci. Technol. 43 (2009), 4555–4560.
182. [182] Lu, S., Duffin, R., Poland, C., Daly, P., Murphy, F., Drost, E., MacNee, W., Stone, V., Donaldson, K., Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation. Environ. Health Perspect. 117 (2009), 241–247.
183. [183] Mo, Y., Mo, Y., Zhu, X., Mo, Y., Zhu, X., Hu, X., Tollerud, D.J., Zhang, Q., Cytokine and NO release from peripheral blood neutrophils after exposure to metal nanoparticles: in vitro and ex vivo studies. Nanotoxicology 2 (2008), 79–87.
184. [184] Cronholm, P., Karlsson, H.L., Hedberg, J., Lowe, T.A., Winnberg, L., Elihn, K., Wallinder, I.O., Möller, L., Intracellular uptake and toxicity of Ag and CuO nanoparticles: a comparison between nanoparticles and their corresponding metal ions. Small 9 (2013), 970–982.
185. [185] Ortega, R., Bresson, C., Darolles, C., Gautier, C., Roudeau, S., Perrin, L., Janin, M., Floriani, M., Aloin, V., Carmona, A., Low-solubility particles and a Trojan-horse type mechanism of toxicity: the case of cobalt oxide on human lung cells. Part. Fibre Toxicol., 11, 2014, 14.
186. [186] Sandri, G., Bonferoni, M.C., Rossi, S., Ferrari, F., Boselli, C., Caramella, C., Insulin-loaded nanoparticles based on N-trimethyl chitosan: in vitro (Caco-2 model) and ex vivo (excised rat jejunum, duodenum, and ileum) evaluation of penetration enhancement properties. AAPS PharmSciTech 11 (2010), 362–371.
187. [187] Kawata, K., Osawa, M., Okabe, S., In vitro toxicity of silver nanoparticles at noncytotoxic doses to HepG2 human hepatoma cells. Environ. Sci. Technol. 43 (2009), 6046–6051.
188. [188] Feoktistova, M., Wallberg, F., Tenev, T., Geserick, P., Leverkus, M., Meier, P., Techniques to distinguish apoptosis from necroptosis. Cold Spring Harbor Protocols, 2016, 2016 (pdb. top070375).
189. [189] Galluzzi, L., Kepp, O., Krautwald, S., Kroemer, G., Linkermann, A., Molecular Mechanisms of Regulated Necrosis, Seminars in Cell & Developmental Biology. 2014, Elsevier, 24–32.
190. [190] Kaczmarek, A., Vandenabeele, P., Krysko, D.V., Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38 (2013), 209–223.
191. [191] Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., Kroemer, G., Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat. Rev. Mol. Cell Biol. 11 (2010), 700–714.
192. [192] Klionsky, D.J., Abdalla, F.C., Abeliovich, H., Abraham, R.T., Acevedo-Arozena, A., Adeli, K., Agholme, L., Agnello, M., Agostinis, P., Aguirre-Ghiso, J.A., Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8 (2012), 445–544.
193. [193] Mizushima, N., Yoshimori, T., Levine, B., Methods in mammalian autophagy research. Cell 140 (2010), 313–326.
194. [194] Tasdemir, E., Galluzzi, L., Maiuri, M.C., Criollo, A., Vitale, I., Hangen, E., Modjtahedi, N., Kroemer, G., Methods for assessing autophagy and autophagic cell death. Autophagosome Phagosome, 2008, 29–76.
195. [195] Ma, X., Wu, Y., Jin, S., Tian, Y., Zhang, X., Zhao, Y., Yu, L., Liang, X.-J., Gold nanoparticles induce autophagosome accumulation through size-dependent nanoparticle uptake and lysosome impairment. ACS Nano 5 (2011), 8629–8639.
196. [196] Seleverstov, O., Zabirnyk, O., Zscharnack, M., Bulavina, L., Nowicki, M., Heinrich, J.-M., Yezhelyev, M., Emmrich, F., O'Regan, R., Bader, A., Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation. Nano Lett. 6 (2006), 2826–2832.
197. [197] Stern, S.T., Zolnik, B.S., McLeland, C.B., Clogston, J., Zheng, J., McNeil, S.E., Induction of autophagy in porcine kidney cells by quantum dots: a common cellular response to nanomaterials?. Toxicol. Sci. 106 (2008), 140–152.
198. [198] Johnson-Lyles, D.N., Peifley, K., Lockett, S., Neun, B.W., Hansen, M., Clogston, J., Stern, S.T., McNeil, S.E., Fullerenol cytotoxicity in kidney cells is associated with cytoskeleton disruption, autophagic vacuole accumulation, and mitochondrial dysfunction. Toxicol. Appl. Pharmacol. 248 (2010), 249–258.
199. [199] Li, J.J., Hartono, D., Ong, C.-N., Bay, B.-H., Yung, L.-Y.L., Autophagy and oxidative stress associated with gold nanoparticles. Biomaterials 31 (2010), 5996–6003.
200. [200] Wu, Y.-N., Yang, L.-X., Shi, X.-Y., Li, I.-C., Biazik, J.M., Ratinac, K.R., Chen, D.-H., Thordarson, P., Shieh, D.-B., Braet, F., The selective growth inhibition of oral cancer by iron core-gold shell nanoparticles through mitochondria-mediated autophagy. Biomaterials 32 (2011), 4565–4573.
201. [201] Khan, M.I., Mohammad, A., Patil, G., Naqvi, S., Chauhan, L., Ahmad, I., Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles. Biomaterials 33 (2012), 1477–1488.
202. [202] Li, C., Liu, H., Sun, Y., Wang, H., Guo, F., Rao, S., Deng, J., Zhang, Y., Miao, Y., Guo, C., PAMAM nanoparticles promote acute lung injury by inducing autophagic cell death through the Akt-TSC2-mTOR signaling pathway. J. Mol. Cell Biol. 1 (2009), 37–45.
203. [203] Liu, H., Zhang, Y., Yang, N., Zhang, Y., Liu, X., Li, C., Zhao, Y., Wang, Y., Zhang, G., Yang, P., A functionalized single-walled carbon nanotube-induced autophagic cell death in human lung cells through Akt–TSC2-mTOR signaling. Cell Death Dis., 2, 2011, e159.
204. [204] Yu, K.-N., Yoon, T.-J., Minai-Tehrani, A., Kim, J.-E., Park, S.J., Jeong, M.S., Ha, S.-W., Lee, J.-K., Kim, J.S., Cho, M.-H., Zinc oxide nanoparticle induced autophagic cell death and mitochondrial damage via reactive oxygen species generation. Toxicol. in Vitro 27 (2013), 1187–1195.
205. [205] Zhao, Y., Howe, J.L., Yu, Z., Leong, D.T., Chu, J.J.H., Loo, J.S.C., Ng, K.W., Exposure to titanium dioxide nanoparticles induces autophagy in primary human keratinocytes. Small 9 (2013), 387–392.
206. [206] Song, W., Soo Lee, S., Savini, M., Popp, L., Colvin, V.L., Segatori, L., Ceria nanoparticles stabilized by organic surface coatings activate the lysosome-autophagy system and enhance autophagic clearance. ACS Nano 8 (2014), 10328–10342.
207. [207] Limbach, L.K., Wick, P., Manser, P., Grass, R.N., Bruinink, A., Stark, W.J., Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress. Environ. Sci. Technol. 41 (2007), 4158–4163.
208. [208] Sabbioni, E., Fortaner, S., Farina, M., Del Torchio, R., Olivato, I., Petrarca, C., Bernardini, G., Mariani-Costantini, R., Perconti, S., Di Giampaolo, L., Cytotoxicity and morphological transforming potential of cobalt nanoparticles, microparticles and ions in Balb/3 T3 mouse fibroblasts: an in vitro model. Nanotoxicology 8 (2014), 455–464.
209. [209] Apopa, P.L., Qian, Y., Shao, R., Guo, N.L., Schwegler-Berry, D., Pacurari, M., Porter, D., Shi, X., Vallyathan, V., Castranova, V., Iron oxide nanoparticles induce human microvascular endothelial cell permeability through reactive oxygen species production and microtubule remodeling. Part. Fibre Toxicol., 6, 2009, 1.
210. [210] Omatsu, T., Naito, Y., Handa, O., Hayashi, N., Mizushima, K., Qin, Y., Hirata, I., Adachi, S., Okayama, T., Kishimoto, E., Involvement of reactive oxygen species in indomethacin-induced apoptosis of small intestinal epithelial cells. J. Gastroenterol. 44 (2009), 30–34.
211. [211] Shi, Y., Tang, B., Yu, P.-W., Tang, B., Hao, Y.-X., Lei, X., Luo, H.-X., Zeng, D.-Z., Autophagy protects against oxaliplatin-induced cell death via ER stress and ROS in Caco-2 cells. PLoS One, 7, 2012, e51076.
212. [212] Devasagayam, T., Boloor, K., Ramasarma, T., Methods for estimating lipid peroxidation: an analysis of merits and demerits. Indian J. Biochem. Biophys. 40 (2003), 300–308.
213. [213] Milatovic, D., Montine, T.J., Aschner, M., Measurement of Isoprostanes as Markers of Oxidative Stress. In Vitro Neurotoxicology, 2011, Springer, 195–204.
214. [214] Stone, V., Johnston, H., Schins, R.P., Development of in vitro systems for nanotoxicology: methodological considerations. Crit. Rev. Toxicol. 39 (2009), 613–626.
215. [215] Suzuki, Y.J., Carini, M., Butterfield, D.A., Protein carbonylation. Antioxid. Redox Signal., 12, 2010, 323.
216. [216] Baraibar, M.A., Ladouce, R., Friguet, B., Proteomic quantification and identification of carbonylated proteins upon oxidative stress and during cellular aging. J. Proteome 92 (2013), 63–70.
217. [217] Tamarit, J., de Hoogh, A., Obis, E., Alsina, D., Cabiscol, E., Ros, J., Analysis of oxidative stress-induced protein carbonylation using fluorescent hydrazides. J. Proteome 75 (2012), 3778–3788.
218. [218] Driessen, M.D., Ossig, R., Schnekenburger, J., Vennemann, A., Wiemann, M., Luch, A., Haase, A., Protein carbonylation as a marker of oxidative stress induced by nanoparticles: analysis of 16 inorganic nanoparticles. Toxicol. Lett., S192, 2014.
219. [219] Bollineni, R.C., Hoffmann, R., Fedorova, M., Proteome-wide profiling of carbonylated proteins and carbonylation sites in HeLa cells under mild oxidative stress conditions. Free Radic. Biol. Med. 68 (2014), 186–195.
220. [220] Fedorova, M., Bollineni, R.C., Hoffmann, R., Protein carbonylation as a major hallmark of oxidative damage: update of analytical strategies. Mass Spectrom. Rev. 33 (2014), 79–97.
221. [221] Driessen, M.D., Mues, S., Vennemann, A., Hellack, B., Bannuscher, A., Vimalakanthan, V., Riebeling, C., Ossig, R., Wiemann, M., Schnekenburger, J., Proteomic analysis of protein carbonylation: a useful tool to unravel nanoparticle toxicity mechanisms. Part. Fibre Toxicol., 12, 2015, 1.
222. [222] Coffey, C.M., Analytical Method Development for the Detection and Analysis of Protein Carbonyls. 2015.
223. [223] Wehr, N.B., Levine, R.L., Quantification of protein carbonylation. Cell Senescence Methods Protoc., 2013, 265–281.
224. [224] Colognato, R., Bonelli, A., Ponti, J., Farina, M., Bergamaschi, E., Sabbioni, E., Migliore, L., Comparative genotoxicity of cobalt nanoparticles and ions on human peripheral leukocytes in vitro. Mutagenesis 23 (2008), 377–382.
225. [225] Papageorgiou, I., Brown, C., Schins, R., Singh, S., Newson, R., Davis, S., Fisher, J., Ingham, E., Case, C., The effect of nano-and micron-sized particles of cobalt–chromium alloy on human fibroblasts in vitro. Biomaterials 28 (2007), 2946–2958.
226. [226] Ponti, J., Sabbioni, E., Munaro, B., Broggi, F., Marmorato, P., Franchini, F., Colognato, R., Rossi, F., Genotoxicity and morphological transformation induced by cobalt nanoparticles and cobalt chloride: an in vitro study in Balb/3T3 mouse fibroblasts. Mutagenesis 24 (2009), 439–445.
227. [227] Piret, J.-P., Vankoningsloo, S., Mejia, J., Noël, F., Boilan, E., Lambinon, F., Zouboulis, C.C., Masereel, B., Lucas, S., Saout, C., Differential toxicity of copper (II) oxide nanoparticles of similar hydrodynamic diameter on human differentiated intestinal Caco-2 cell monolayers is correlated in part to copper release and shape. Nanotoxicology 6 (2012), 789–803.
228. [228] Peters, K., Unger, R.E., Kirkpatrick, C.J., Gatti, A.M., Monari, E., Effects of nano-scaled particles on endothelial cell function in vitro: studies on viability, proliferation and inflammation. J. Mater. Sci. Mater. Med. 15 (2004), 321–325.
229. [229] Xia, T., Kovochich, M., Brant, J., Hotze, M., Sempf, J., Oberley, T., Sioutas, C., Yeh, J.I., Wiesner, M.R., Nel, A.E., Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett. 6 (2006), 1794–1807.
230. [230] ASTM, ASTM E2525-08, Standard Test Method for Evaluation of the Effect of Nanoparticulate Materials on the Formation of Mouse Granulocyte-Macrophage Colonies. 2008, ASTM International, West Conshohocken, PA.
231. [231] ASTM, ASTM E2524-08(2013), Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles. 2013, ASTM International, West Conshohocken, PA.
232. [232] Bregoli, L., Chiarini, F., Gambarelli, A., Sighinolfi, G., Gatti, A.M., Santi, P., Martelli, A.M., Cocco, L., Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. Toxicology 262 (2009), 121–129.
233. [233] Dobrovolskaia, M.A., McNeil, S.E., In vitro Assays for Monitoring Nanoparticle Interaction with Components of the Immune System, Handbook of Immunological Properties of Engineered Nanomaterials. 2013, World Scientific publishing Co. Pte. Ltd, 582–639.
234. [234] Dobrovolskaia, M.A., McNeil, S.E., Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J. Control. Release 172 (2013), 456–466.
235. [235] Farrera, C., Fadeel, B., It takes two to tango: understanding the interactions between engineered nanomaterials and the immune system. Eur. J. Pharm. Biopharm. 95 (2015), 3–12.
236. [236] Ledur, A., Fitting, C., David, B., Hamberger, C., Cavaillon, J.-M., Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. J. Immunol. Methods 186 (1995), 171–179.
237. [237] Moon, E.-Y., Yi, G.-H., Kang, J.-S., Lim, J.-S., Kim, H.-M., Pyo, S., An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide nanoparticles. J. Immunotoxicol. 8 (2011), 56–67.
238. [238] Myerson, J., He, L., Lanza, G., Tollefsen, D., Wickline, S., Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. J. Thromb. Haemost. 9 (2011), 1292–1300.
239. [239] Nabeshi, H., Yoshikawa, T., Matsuyama, K., Nakazato, Y., Arimori, A., Isobe, M., Tochigi, S., Kondoh, S., Hirai, T., Akase, T., Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. Nanotechnology, 23, 2012, 045101.
240. [240] Neun, B.W., Dobrovolskaia, M.A., Qualitative Analysis of Total Complement Activation by Nanoparticles, Characterization of Nanoparticles Intended for Drug Delivery. 2011, 237–245.
241. [241] Agashe, H.B., Dutta, T., Garg, M., Jain, N., Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J. Pharm. Pharmacol. 58 (2006), 1491–1498.
242. [242] Agrawal, P., Gupta, U., Jain, N., Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 28 (2007), 3349–3359.
243. [243] Allard-Vannier, E., Cohen-Jonathan, S., Gautier, J., Herve-Aubert, K., Munnier, E., Souce, M., Legras, P., Passirani, C., Chourpa, I., Pegylated magnetic nanocarriers for doxorubicin delivery: a quantitative determination of stealthiness in vitro and in vivo. Eur. J. Pharm. Biopharm. 81 (2012), 498–505.
244. [244] Asthana, A., Chauhan, A.S., Diwan, P.V., Jain, N.K., Poly (amidoamine)(PAMAM) dendritic nanostructures for controlled sitespecific delivery of acidic anti-inflammatory active ingredient. AAPS PharmSciTech 6 (2005), E536–E542.
245. [245] Bhadra, D., Bhadra, S., Jain, S., Jain, N., A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 257 (2003), 111–124.
246. [246] Bhadra, D., Yadav, A., Bhadra, S., Jain, N., Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int. J. Pharm. 295 (2005), 221–233.
247. [247] Frick, S.U., Bacher, N., Baier, G., Mailänder, V., Landfester, K., Steinbrink, K., Functionalized polystyrene nanoparticles trigger human dendritic cell maturation resulting in enhanced CD4 + T cell activation. Macromol. Biosci. 12 (2012), 1637–1647.
248. [248] Gaucher, G., Asahina, K., Wang, J., Leroux, J.-C., Effect of poly (N-vinyl-pyrrolidone)-block-poly (D, L-lactide) as coating agent on the opsonization, phagocytosis, and pharmacokinetics of biodegradable nanoparticles. Biomacromolecules 10 (2009), 408–416.
249. [249] Geary, R.S., Rosie, Z.Y., Watanabe, T., Henry, S.P., Hardee, G.E., Chappell, A., Matson, J., Sasmor, H., Cummins, L., Levin, A.A., Pharmacokinetics of a tumor necrosis factor-α phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos. 31 (2003), 1419–1428.
250. [250] Glass, J.J., Kent, S.J., De Rose, R., Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. Expert Rev. Vaccines 15 (2016), 719–729.
251. [251] Goodman, J.T., Vela Ramirez, J.E., Boggiatto, P.M., Roychoudhury, R., Pohl, N.L., Wannemuehler, M.J., Narasimhan, B., Nanoparticle chemistry and functionalization differentially regulates dendritic cell–nanoparticle interactions and triggers dendritic cell maturation. Part. Part. Syst. Charact. 31 (2014), 1269–1280.
252. [252] Henry, S.P., Beattie, G., Yeh, G., Chappel, A., Giclas, P., Mortari, A., Jagels, M.A., Kornbrust, D.J., Levin, A.A., Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int. Immunopharmacol. 2 (2002), 1657–1666.
253. [253] Huynh, N.T., Morille, M., Bejaud, J., Legras, P., Vessieres, A., Jaouen, G., Benoit, J.-P., Passirani, C., Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect. Pharm. Res. 28 (2011), 3189–3198.
254. [254] Jahromi, M.A.M., Karimi, M., Azadmanesh, K., Manesh, H.N., Hassan, Z.M., Moazzeni, S.M., The effect of chitosan-tripolyphosphate nanoparticles on maturation and function of dendritic cells. Comp. Clin. Pathol. 23 (2014), 1421–1427.
255. [255] Jun, E.-A., Lim, K.-M., Kim, K., Bae, O.-N., Noh, J.-Y., Chung, K.-H., Chung, J.-H., Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity. Nanotoxicology 5 (2011), 157–167.
256. [256] Knuschke, T., Sokolova, V., Rotan, O., Wadwa, M., Tenbusch, M., Hansen, W., Staeheli, P., Epple, M., Buer, J., Westendorf, A.M., Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection. J. Immunol. 190 (2013), 6221–6229.
257. [257] Laloy, J., Robert, S., Marbehant, C., Mullier, F., Mejia, J., Piret, J.-P., Lucas, S., Chatelain, B., Dogné, J.-M., Toussaint, O., Validation of the calibrated thrombin generation test (cTGT) as the reference assay to evaluate the procoagulant activity of nanomaterials. Nanotoxicology 6 (2012), 213–232.
258. [258] Malik, N., Wiwattanapatapee, R., Klopsch, R., Lorenz, K., Frey, H., Weener, J., Meijer, E., Paulus, W., Duncan, R., Dendrimers:: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control. Release 65 (2000), 133–148.
259. [259] Merkel, O.M., Urbanics, R., Bedőcs, P., Rozsnyay, Z., Rosivall, L., Toth, M., Kissel, T., Szebeni, J., In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly (ethylene glycol) block copolymers. Biomaterials 32 (2011), 4936–4942.
260. [260] Moyano, D.F., Goldsmith, M., Solfiell, D.J., Landesman-Milo, D., Miranda, O.R., Peer, D., Rotello, V.M., Nanoparticle hydrophobicity dictates immune response. J. Am. Chem. Soc. 134 (2012), 3965–3967.
261. [261] Radomski, A., Jurasz, P., Alonso-Escolano, D., Drews, M., Morandi, M., Malinski, T., Radomski, M.W., Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 146 (2005), 882–893.
262. [262] Raetz, C.R., Whitfield, C., Lipopolysaccharide endotoxins. Annu. Rev. Biochem., 71, 2002, 635.
263. [263] Senn, J.J., Burel, S., Henry, S.P., Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of toll-like receptor 9 or myeloid differentiation factor 88. J. Pharmacol. Exp. Ther. 314 (2005), 972–979.
264. [264] Shan, X., Yuan, Y., Liu, C., Tao, X., Sheng, Y., Xu, F., Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles. Biomed. Microdevices 11 (2009), 1187–1194.
265. [265] Simberg, D., Zhang, W.-M., Merkulov, S., McCrae, K., Park, J.-H., Sailor, M.J., Ruoslahti, E., Contact activation of kallikrein–kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo. J. Control. Release 140 (2009), 301–305.
266. [266] Szebeni, J., Alving, C.R., Rosivall, L., Bünger, R., Baranyi, L., Bedöcs, P., Tóth, M., Barenholz, Y., Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J. Liposome Res. 17 (2007), 107–117.
267. [267] Tomić, S., Đokić, J., Vasilijić, S., Ogrinc, N., Rudolf, R., Pelicon, P., Vučević, D., Milosavljević, P., Janković, S., Anžel, I., Size-dependent effects of gold nanoparticles uptake on maturation and antitumor functions of human dendritic cells in vitro. PLoS One, 9, 2014, e96584.
268. [268] Monteiro-Riviere, N.A., Inman, A.O., Zhang, L., Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharmacol. 234 (2009), 222–235.
269. [269] Yin, L., Ding, J., He, C., Cui, L., Tang, C., Yin, C., Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 30 (2009), 5691–5700.
270. [270] Buyukozturk, F., Benneyan, J.C., Carrier, R.L., Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics. J. Control. Release 142 (2010), 22–30.
271. [271] Brun, E., Barreau, F., Veronesi, G., Fayard, B., Sorieul, S., Chanéac, C., Carapito, C., Rabilloud, T., Mabondzo, A., Herlin-Boime, N., Titanium dioxide nanoparticle impact and translocation through ex vivo, in vivo and in vitro gut epithelia. Part. Fibre Toxicol., 11, 2014, 13.
272. [272] Beloqui, A., Solinís, M.Á., Gascón, A.R., del Pozo-Rodríguez, A., Rieux, A.d., Préat, V., Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J. Control. Release 166 (2013), 115–123.
273. [273] Botha, N., Gehringer, M.M., Downing, T.G., van de Venter, M., Shephard, E.G., The role of microcystin-LR in the induction of apoptosis and oxidative stress in CaCo2 cells. Toxicon 43 (2004), 85–92.
274. [274] Riss, T., Moravec, R., Niles, A., Benink, H., Worzella, T., Minor, L., Cell Viability Assays, 2004.
275. [275] Anguissola, S., Garry, D., Salvati, A., O'Brien, P.J., Dawson, K.A., High content analysis provides mechanistic insights on the pathways of toxicity induced by amine-modified polystyrene nanoparticles. PLoS One, 9, 2014, e108025.
276. [276] Elmore, S., Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35 (2007), 495–516.
277. [277] Repetto, G., del Peso, A., Zurita, J.L., Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat. Protoc. 3 (2008), 1125–1131.
278. [278] Narai, A., Arai, S., Shimizu, M., Rapid decrease in transepithelial electrical resistance of human intestinal Caco-2 cell monolayers by cytotoxic membrane perturbents. Toxicol. in Vitro 11 (1997), 347–354.
279. [279] Aranda, A., Sequedo, L., Tolosa, L., Quintas, G., Burello, E., Castell, J., Gombau, L., Dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay: a quantitative method for oxidative stress assessment of nanoparticle-treated cells. Toxicol. in Vitro 27 (2013), 954–963.
280. [280] Marchesi, E., Rota, C., Fann, Y.C., Chignell, C.F., Mason, R.P., Photoreduction of the fluorescent dye 2′-7′-dichlorofluorescein: a spin trapping and direct electron spin resonance study with implications for oxidative stress measurements. Free Radic. Biol. Med. 26 (1999), 148–161.
281. [281] Crow, J.P., Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitritein vitro: implications for intracellular measurement of reactive nitrogen and oxygen species. Nitric Oxide 1 (1997), 145–157.
282. [282] Gutteridge, J., Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin. Chem. 41 (1995), 1819–1828.
283. [283] Rice-Evans, C., Burdon, R., Free radical-lipid interactions and their pathological consequences. Prog. Lipid Res. 32 (1993), 71–110.
284. [284] Raha, S., Robinson, B.H., Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 25 (2000), 502–508.
285. [285] Ramana, K.V., Srivastava, S., Singhal, S.S., Lipid peroxidation products in human health and disease. Oxidative Med. Cell. Longev., 2013, 2013.
286. [286] Betteridge, D.J., What is oxidative stress?. Metabolism 49 (2000), 3–8.
287. [287] Halprin, K.M., Ohkawara, A., The measurement of glutathione in human epidermis using glutathione Reductase1. J. Investig. Dermatol. 48 (1967), 149–152.
288. [288] Kannan, K., Jain, S.K., Oxidative stress and apoptosis. Pathophysiology 7 (2000), 153–163.
289. [289] Galluzzi, L., Vitale, I., Abrams, J., Alnemri, E., Baehrecke, E., Blagosklonny, M., Dawson, T., Dawson, V., El-Deiry, W., Fulda, S., Molecular definitions of cell death subroutines: recommendations of the nomenclature committee on cell death 2012. Cell Death Differ. 19 (2012), 107–120.
290. [290] Andón, F.T., Fadeel, B., Programmed cell death: molecular mechanisms and implications for safety assessment of nanomaterials. Acc. Chem. Res. 46 (2012), 733–742.
291. [291] Fadeel, B., Orrenius, S., Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J. Intern. Med. 258 (2005), 479–517.
292. [292] Meier, P., Vousden, K.H., Lucifer's labyrinth—ten years of path finding in cell death. Mol. Cell 28 (2007), 746–754.
293. [293] Jayakiran, M., Apoptosis-biochemistry: a mini review. J. Clin. Exp. Pathol., 2015, 2015.
294. [294] Fan, T.-J., Han, L.-H., Cong, R.-S., Liang, J., Caspase family proteases and apoptosis. Acta Biochim. Biophys. Sin. 37 (2005), 719–727.
295. [295] Bregoli, L., Benetti, F., Venturini, M., Sabbioni, E., ECSIN's methodological approach for hazard evaluation of engineered nanomaterials. J. Phys. Conf. Ser., 2013, 012017 (IOP Publishing).
296. [296] Ozawa, T., Oxidative damage and fragmentation of mitochondrial DNA in cellular apoptosis. Biosci. Rep. 17 (1997), 237–250.
297. [297] Levine, B., Klionsky, D.J., Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 6 (2004), 463–477.
298. [298] Boya, P., Reggiori, F., Codogno, P., Emerging regulation and functions of autophagy. Nat. Cell Biol. 15 (2013), 713–720.
299. [299] Luebke, R., Immunotoxicant screening and prioritization in the twenty-first century. Toxicol. Pathol. 40 (2012), 294–299.
300. [300] Xiang, S.D., Fuchsberger, M., Karlson, T.D.L., Hardy, C.L., Selomulya, C., Plebanski, M., Nanoparticles, Immunomodulation and Vaccine Delivery. 2013, World Scientific Publishing, Hackensack, NJ, USA.
301. [301] Dobrovolskaia, M.A., Aggarwal, P., Hall, J.B., McNeil, S.E., Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5 (2008), 487–495.
302. [302] Mowat, A.M., Agace, W.W., Regional specialization within the intestinal immune system. Nat. Rev. Immunol. 14 (2014), 667–685.
303. [303] Lu, S., Duffin, R., Poland, C., Daly, P., Murphy, F., Drost, E., MacNee, W., Stone, V., Donaldson, K., Efficacy of simple short-term in vitro assays for predicting the potential of metal oxide nanoparticles to cause pulmonary inflammation. Environ. Health Perspect., 117, 2009, 241.
304. [304] OECD, Test No. 476: In vitro Mammalian Cell Gene Mutation Test, OECD Publishing.
305. [305] OECD, Test No. 473: In vitro Mammalian Chromosomal Aberration Test, OECD Publishing.
306. [306] OECD, Test No. 487: In vitro Mammalian Cell Micronucleus Test, OECD Publishing.
307. [307] Fenech, M., Morley, A., Solutions to the kinetic problem in the micronucleus assay. Cytobios 43 (1984), 233–246.
308. [308] Kirsch-Volders, M., Sofuni, T., Aardema, M., Albertini, S., Eastmond, D., Fenech, M., Ishidate, M., Kirchner, S., Lorge, E., Morita, T., Report from the in vitro micronucleus assay working group. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 540 (2003), 153–163.
309. [309] Foss, A.C., Peppas, N.A., Investigation of the cytotoxicity and insulin transport of acrylic-based copolymer protein delivery systems in contact with Caco-2 cultures. Eur. J. Pharm. Biopharm. 57 (2004), 447–455.
310. [310] Ferruzza, S., Scacchi, M., Scarino, M., Sambuy, Y., Iron and copper alter tight junction permeability in human intestinal Caco-2 cells by distinct mechanisms. Toxicol. in Vitro 16 (2002), 399–404.
311. [311] Bouwmeester, H., Poortman, J., Peters, R.J., Wijma, E., Kramer, E., Makama, S., Puspitaninganindita, K., Marvin, H.J., Peijnenburg, A.A., Hendriksen, P.J., Characterization of translocation of silver nanoparticles and effects on whole-genome gene expression using an in vitro intestinal epithelium coculture model. ACS Nano 5 (2011), 4091–4103.
312. [312] Zhou, Y., Yokel, R.A., The chemical species of aluminum influences its paracellular flux across and uptake into Caco-2 cells, a model of gastrointestinal absorption. Toxicol. Sci. 87 (2005), 15–26.
313. [313] Bajak, E., Fabbri, M., Ponti, J., Gioria, S., Ojea-Jiménez, I., Collotta, A., Mariani, V., Gilliland, D., Rossi, F., Gribaldo, L., Changes in Caco-2 cells transcriptome profiles upon exposure to gold nanoparticles. Toxicol. Lett. 233 (2015), 187–199.
314. [314] Fisichella, M., Berenguer, F., Steinmetz, G., Auffan, M., Rose, J., Prat, O., Intestinal toxicity evaluation of TiO 2 degraded surface-treated nanoparticles: a combined physico-chemical and toxicogenomics approach in caco-2 cells. Part. Fibre Toxicol., 9, 2012, 1.
315. [315] Moos, P.J., Olszewski, K., Honeggar, M., Cassidy, P., Leachman, S., Woessner, D., Cutler, N.S., Veranth, J.M., Responses of human cells to ZnO nanoparticles: a gene transcription study. Metallomics 3 (2011), 1199–1211.
316. [316] Tilton, S.C., Karin, N.J., Tolic, A., Xie, Y., Lai, X., Hamilton, R.F. Jr., Waters, K.M., Holian, A., Witzmann, F.A., Orr, G., Three human cell types respond to multi-walled carbon nanotubes and titanium dioxide nanobelts with cell-specific transcriptomic and proteomic expression patterns. Nanotoxicology 8 (2014), 533–548.
317. [317] Rabilloud, T., Chevallet, M., Luche, S., Lelong, C., Two-dimensional gel electrophoresis in proteomics: past, present and future. J. Proteome 73 (2010), 2064–2077.
318. [318] Blazer-Yost, B.L., Banga, A., Amos, A., Chernoff, E., Lai, X., Li, C., Mitra, S., Witzmann, F.A., Effect of carbon nanoparticles on renal epithelial cell structure, barrier function, and protein expression. Nanotoxicology 5 (2011), 354–371.
319. [319] Teeguarden, J.G., Webb-Robertson, B.-J., Waters, K.M., Murray, A.R., Kisin, E.R., Varnum, S.M., Jacobs, J.M., Pounds, J.G., Zanger, R.C., Shvedova, A.A., Comparative proteomics and pulmonary toxicity of instilled single-walled carbon nanotubes, crocidolite asbestos, and ultrafine carbon black in mice. Toxicol. Sci. 120 (2011), 123–135.
320. [320] Neilson, K.A., Ali, N.A., Muralidharan, S., Mirzaei, M., Mariani, M., Assadourian, G., Lee, A., Van Sluyter, S.C., Haynes, P.A., Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics 11 (2011), 535–553.
321. [321] Xie, F., Liu, T., Qian, W.-J., Petyuk, V.A., Smith, R.D., Liquid chromatography-mass spectrometry-based quantitative proteomics. J. Biol. Chem. 286 (2011), 25443–25449.
322. [322] Helsens, K., Martens, L., Vandekerckhove, J., Gevaert, K., Mass Spectrometry-Driven Proteomics: An Introduction, Gel-Free Proteomics: Methods and Protocols. 2011, 1–27.
323. [323] Lai, X., Blazer-Yost, B.L., Clack, J.W., Fears, S.L., Mitra, S., Ntim, S.A., Ringham, H.N., Witzmann, F.A., Protein expression profiles of intestinal epithelial co-cultures: effect of functionalised carbon nanotube exposure. Int. J. Biomed. Nanosci. Nanotechnol. 3 (2013), 127–162.
324. [324] Blanksby, S.J., Mitchell, T.W., Advances in mass spectrometry for lipidomics. Annu. Rev. Anal. Chem. 3 (2010), 433–465.
325. [325] Hsu, F.-F., Turk, J., Electrospray ionization with low-energy collisionally activated dissociation tandem mass spectrometry of glycerophospholipids: mechanisms of fragmentation and structural characterization. J. Chromatogr. B 877 (2009), 2673–2695.
326. [326] Ivanova, P.T., Milne, S.B., Myers, D.S., Brown, H.A., Lipidomics: a mass spectrometry based systems level analysis of cellular lipids. Curr. Opin. Chem. Biol. 13 (2009), 526–531.
327. [327] Shvedova, A.A., Pietroiusti, A., Fadeel, B., Kagan, V.E., Mechanisms of carbon nanotube-induced toxicity: focus on oxidative stress. Toxicol. Appl. Pharmacol. 261 (2012), 121–133.
328. [328] Raesch, S.S., Tenzer, S., Storck, W., Rurainski, A., Selzer, D., Ruge, C.A., Perez-Gil, J., Schaefer, U.F., Lehr, C.-M., Proteomic and lipidomic analysis of nanoparticle corona upon contact with lung surfactant reveals differences in protein, but not lipid composition. ACS Nano 9 (2015), 11872–11885.
329. [329] Tedesco, S., Bayat, N., Danielsson, G., Buque, X., Aspichueta, P., Fresnedo, O., Cristobal, S., Proteomic and lipidomic analysis of primary mouse hepatocytes exposed to metal and metal oxide nanoparticles. J. Integr. OMICS 5 (2015), 44–57.
330. [330] Gioria, S., Lobo Vicente, J., Barboro, P., La Spina, R., Tomasi, G., Urbán, P., Kinsner-Ovaskainen, A., Rossi, F., Chassaigne, H., A combined proteomics and metabolomics approach to assess the effects of gold nanoparticles in vitro. Nanotoxicology, 2015, 1–59.
331. [331] Chadha, N., Chaturvedi, S., Lal, S., Mishra, A.K., Pulicharla, R., Cledon, M., Brar, S.K., Surampalli, R., Engineered nanoparticles associated metabolomics. J. Hazard. Toxic Radioact. Waste, 20, 2015, B4015003.
332. [332] Martel, J., Wu, C.-Y., Hung, C.-Y., Wong, T.-Y., Cheng, A.-J., Cheng, M.-L., Shiao, M.-S., Young, J.D., Fatty acids and small organic compounds bind to mineralo-organic nanoparticles derived from human body fluids as revealed by metabolomic analysis. Nanoscale 8 (2016), 5537–5545.
333. [333] Feng, J., Li, J., Wu, H., Chen, Z., Metabolic responses of HeLa cells to silica nanoparticles by NMR-based metabolomic analyses. Metabolomics 9 (2013), 874–886.
334. [334] Lee, S.-H., Wang, T.-Y., Hong, J.-H., Cheng, T.-J., Lin, C.-Y., NMR-based metabolomics to determine acute inhalation effects of nano-and fine-sized ZnO particles in the rat lung. Nanotoxicology, 2016, 1–11.
335. [335] Bunaciu, A.A., Fleschin, S., Aboul-Enein, H.Y., Biomedical investigations using Fourier transform-infrared microspectroscopy. Crit. Rev. Anal. Chem. 44 (2014), 270–276.
336. [336] Paunesku, T., Vogt, S., Maser, J., Lai, B., Woloschak, G., X-ray fluorescence microprobe imaging in biology and medicine. J. Cell. Biochem. 99 (2006), 1489–1502.
337. [337] Dobrovolskaia, M.A., Germolec, D.R., Weaver, J.L., Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 4 (2009), 411–414.
338. [338] Smulders, S., Kaiser, J.-P., Zuin, S., Van Landuyt, K.L., Golanski, L., Vanoirbeek, J., Wick, P., Hoet, P.H., Contamination of nanoparticles by endotoxin: evaluation of different test methods. Part. Fibre Toxicol., 9, 2012, 1.
339. [339] Vallhov, H., Interactions of Engineered and Endogenous Nanoparticles with Cells in the Immune System, Institutionen för Medicin/Department of Medicine. 2010.
340. [340] Vetten, M.A., Yah, C.S., Singh, T., Gulumian, M., Challenges facing sterilization and depyrogenation of nanoparticles: effects on structural stability and biomedical applications. Nanomed.: Nanotechnol., Biol. Med. 10 (2014), 1391–1399.
341. [341] Zanella, M., Ciappellano, S.G., Venturini, M., Tedesco, E., Manodori, L., Benetti, F., Nutraceuticals and nanotechnology. Agro FOOD Industry Hi Tech 26 (2015), 26–31.
342. [342] Yokel, R.A., MacPhail, R.C., Engineered nanomaterials: exposures, hazards, and risk prevention. J. Occup. Med. Toxicol., 6, 2011.
343. [343] Powell, J.J., Faria, N., Thomas-McKay, E., Pele, L.C., Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J. Autoimmun. 34 (2010), J226–J233.
344. [344] Teeguarden, J.G., Hinderliter, P.M., Orr, G., Thrall, B.D., Pounds, J.G., Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol. Sci. 95 (2007), 300–312.
345. [345] Mahler, G.J., Esch, M.B., Tako, E., Southard, T.L., Archer, S.D., Glahn, R.P., Shuler, M.L., Oral exposure to polystyrene nanoparticles affects iron absorption. Nat. Nanotechnol. 7 (2012), 264–271.
346. [346] Doak, S., Griffiths, S., Manshian, B., Singh, N., Williams, P., Brown, A., Jenkins, G., Confounding experimental considerations in nanogenotoxicology. Mutagenesis 24 (2009), 285–293.
347. [347] Sharifi, S., Behzadi, S., Laurent, S., Forrest, M.L., Stroeve, P., Mahmoudi, M., Toxicity of nanomaterials. Chem. Soc. Rev. 41 (2012), 2323–2343.
348. [348] Dobrovolskaia, M.A., Neun, B.W., Clogston, J.D., Ding, H., Ljubimova, J., McNeil, S.E., Ambiguities in applying traditional Limulus amebocyte lysate tests to quantify endotoxin in nanoparticle formulations. Nanomedicine 5 (2010), 555–562.
349. [349] Oberdörster, E., Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ. Health Perspect., 112, 2004, 1058.
350. [350] Casey, A., Herzog, E., Davoren, M., Lyng, F., Byrne, H., Chambers, G., Spectroscopic analysis confirms the interactions between single walled carbon nanotubes and various dyes commonly used to assess cytotoxicity. Carbon 45 (2007), 1425–1432.
351. [351] Wörle-Knirsch, J., Pulskamp, K., Krug, H., Oops they did it again! Carbon nanotubes hoax scientists in viability assays. Nano Lett. 6 (2006), 1261–1268.
352. [352] Ranaldi, G., Marigliano, I., Vespignani, I., Perozzi, G., Sambuy, Y., The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line. J. Nutr. Biochem. 13 (2002), 157–167.
353. [353] NanoValid, http://www.nanovalid.eu.
354. [354] QualityNano, http://www.qualitynano.eu.
355. [355] NANoREG, http://www.nanoreg.eu.
356. [356] M.R.o.N. (MARINA-FP7), http://www.marina-fp7.eu/.
357. [357] Farcal, L., Andón, F.T., Di Cristo, L., Rotoli, B.M., Bussolati, O., Bergamaschi, E., Mech, A., Hartmann, N.B., Rasmussen, K., Riego-Sintes, J., Comprehensive in vitro toxicity testing of a panel of representative oxide nanomaterials: first steps towards an intelligent testing strategy. PLoS One, 10, 2015, e0127174.
358. [358] Cooper, R.G., Third-generation new product processes. J. Prod. Innov. Manag. 11 (1994), 3–14.